51 results about "Recombinant Chimeric Proteins" patented technology

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by a recombinant chimeric protein between human interleukin-2 (IL2) and Bax. The chimeric protein specifically targets IL2 receptor (IL2R)-expressing cells and induces cell-specific apoptosis.

Described herein are antibodies that bind to human tumor necrosis factor alpha (hTNFα). And list the nucleotide sequence of antibody heavy chain and light chain variable region and its derived amino acid sequence. The heavy chain and light chain variable region genes are respectively connected with the human immunoglobulin gamma 1 (hIgG1) heavy chain constant region and human kappa (k) light chain constant region genes to form a chimeric gene. Then, the vector containing the chimeric gene is introduced into the host cell line to express the antibody protein. This recombinant chimeric antibody protein can neutralize the activity of hTNFα in vitro, and is suitable for treating patients with excessive secretion of harmful hTNFα, including certain inflammations, such as rheumatoid arthritis and Crohn's disease.

The invention discloses a recombinant human pepsinogen II isozyme chimeric protein, and a preparation method and applications thereof. The preparation method comprises the steps as follows: by taking gene sequences of two isozymes of recombinant human pepsinogen II as a template, carrying out PCR (polymerase chain reaction) splicing to obtain a chimeric protein coding gene sequence, constructing recombinant expression plasmids, transforming the screened positive clone plasmids into expression host cells, screening an efficiently-expressed recombinant chimeric protein strain, carrying out enlargement culture on the cells and inducing expression chimeric protein, and purifying to obtain the recombinant human pepsinogen II isozyme chimeric protein. The invention further discloses the applications of the recombinant human pepsinogen II isozyme chimeric protein in preparing monoclonal antibodies and multiresistant serums or pepsinogen II kit calibration products. A great amount of stably expressed recombinant human pepsinogen II isozyme chimeric protein can be produced by utilizing a genetic engineering technology, and one protein has two chimeric protein sequences of the human pepsinogen II.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an EGFRvIII monoclonal antibody, conferring specific immunity against EGFRvIII positive cells. The TCR KO engineered immune cells endowed with such CARs are particularly suited for treating lung cancer, anal cancers and glioblastoma multiforme.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

The present invention is directed to DNA sequence encoding angiogenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an EGFRvIII monoclonal antibody, conferring specific immunity against EGFRvIII positive cells. The TCR KO engineered immune cells endowed with such CARs are particularly suited for treating lung cancer, anal cancers and glioblastoma multiforme.

The invention discloses a recombinant chimeric protein carrying a hepatitis B virus epitope and the preparation thereof, particularly a recombinant chimeric protein respectively carrying a hepatitis B virus S82, C19, S125, S2[8], S1[93] or C117 epitope, and a recombinant chimeric protein simultaneously carrying hepatitis B virus S82, C19, S125, S2[8], S1[93] and C117 epitopes, and through the immunology WesternBlot detection, each recombinant protein not only has the antigen reactivity and the immunogenicity of a VP6F protein, but also has the antigen reactivity and the immunogenicity of the HBV (hepatitis B virus) epitope, does not have infectivity and the side effects of virulence atavism, the intussusception and the like, and has important value for developing new generation RV (Rota Virus) / HBV recombinant chimeric vaccine and reagent.

The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

The invention relates to a human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein, wherein the amino acid sequence of the protein is shown in SEQ ID NO.2. Furthermore, the invention provides a coding gene and a preparation method of the protein as well as an application of the protein in preparation of a rotavirus vaccine. Two segments P[8]deltaVP8* and P[6]deltaVP8* are connected in serial to be expressed into the human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein; the protein can simultaneously induce neutralizing antibodies of major P genotypes P [8], P[4] and P[6] of the human rotavirus, overcome the shortcoming of an existing vaccine which can induce the generation of an antibody only capable of resisting one genotype and greatly enhance immune efficiency; and meanwhile, the protein can avoid a potential risk that oral administration of attenuated vaccine rotavirus possibly induces intestinal invagination, and is applicable to preparation of rotavirus vaccine.

The invention provides a bovine rotavirus VP8* subunit recombinant chimeric protein. According to the bovine rotavirus VP8* subunit recombinant chimeric protein, a T cell epitope polypeptide P2 in a tetanus toxin is introduced into an epitope vaccine of a bovine rotavirus VP8* subunit multi-copy chimeric gene recombinant protein, so that the immune efficacy of the epitope vaccine can be greatly enhanced, cross neutralizing immune protection can be induced, higher neutralizing antibody titer can be induced, and a high-titer anti-P[5] and P[11] genotype-specific rotavirus neutralizing antibody can be induced. The bovine rotavirus VP8* subunit recombinant chimeric protein provided by the invention can be used for preventing and controlling both G6 and G10 type rotaviruses which are mainly pandemic within a world range, and is suitable for preparing a safe and low-cost bovine rotavirus vaccine; in addition, the bovine rotavirus vaccine can be used for effectively reducing the economic loss brought by rotavirus gastroenteritis to cattle rearing by being matched with other rotavirus vaccines researched and developed at present, and has wide market prospects.

The invention provides a serogroup B meningococcus recombinant chimeric protein vaccine and a preparation method thereof. The vaccine contains three recombinant chimeric proteins of P2-fHBP V1, P2-fHBP V2 and P2-fHBP V3, wherein amino acid sequences of the recombinant chimeric proteins are SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively; the contents of all the proteins are 30 to 50mu g / dose; optimally, a vaccine preparation also contains a cryoprotectant or vaccine adjuvant. The invention also provides the preparation method of the three recombinant chimeric proteins. By using the recombinant chimeric proteins formed by linking P2 with serogroup B meningococcus fHBP protein, humoral immune response can be effectively induced, and immunogenicity of fHBP is obviously improved. The vaccine provided by the invention can effectively cover all serogroup B meningococcus strains, thereby providing a broad-spectrum preventing effect on invasive diseases such as cerebrospinal meningitis,bacteremia, pneumonia and pericarditis caused by the serogroup B meningococcus.

The invention provides a bovine infectious rhinotracheitis virus multi-epitope recombinant chimeric protein and an application thereof. The recombinant chimeric protein is formed by rigid linker series connection of a tetanus toxin general T cell epitope polypeptide P2, a bovine infectious rhinotracheitis virus gB antigen epitopes gB-A and gB-B, bovine infectious rhinotracheitis virus gC antigen epitopes gC-A and gC-B, bovine infectious rhinotracheitis virus gD antigen epitopes gD-A, gD-B and gD-C and bovine IL-6. The anti-bovine infectious rhinotracheitis virus antibody level induced by the bovine infectious rhinotracheitis virus multi-epitope recombinant chimeric protein provided by the invention is significantly higher than that of other control groups, and the recombinant chimeric protein is indicated to have good immunogenicity.

Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of urinary tract infections, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for urinary tract infections. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.

The provides methods for generating divergent libraries of recombinant chimeric proteins, comprising identifying a plurality of conserved amino acid sequences, selecting a plurality of consensus amino acid sequences as a backbone corresponding to said conserved amino acid sequences to serve as sites of recombination and as a backbone for recombinant chimeric proteins created, generating overlapping polynucleotides, inducing recombination between said polynucleotides to produce divergent libraries of chimeric polynucleotides wherein the recombinations intentionally take place between the sequences that correspond to the full length consensus amino acids. The advantage is that shuffling between variable regions, while maintaining the consensus backbone, increases the production of active proteins with high diversity, and better properties.